The AI Drug Discovery Capital Stack in 2026: Who Has Raised the Most, Why Their Technical Approaches Actually Differ, and Which Recent Industry and Academic Papers Are Worth a Real Read

Thoughts on Healthcare Markets & Technology Podcast

0:00

-18:16

Paid episode

The full episode is only available to paid subscribers of Thoughts on Healthcare Markets & Technology

The AI Drug Discovery Capital Stack in 2026: Who Has Raised the Most, Why Their Technical Approaches Actually Differ, and Which Recent Industry and Academic Papers Are Worth a Real Read

The phrase "AI drug discovery" obscures more than it reveals — this episode separates the platforms by what they actually do under the hood.

May 04, 2026

∙ Paid

The top of the AI drug discovery capital stack as of April 2026 includes Xaira ($1.3 billion), Eikon (~$1.5 billion), and Isomorphic Labs ($600 million in external capital). This episode separates their technical approaches because the architectural differences matter more than the fundraising headlines for evaluating investment theses.

We examine the di…

Continue reading this post for free, courtesy of Thoughts on Healthcare.

Or purchase a paid subscription.